{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:32:00Z","timestamp":1789594320737,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We have conducted a retrospective, single\u2010centre analysis of 20 patients with relapsed or refractory FLT3\u2010mutated acute myeloid leukaemia (FLT3m AML) who received a salvage quadruplet regimen consisting of gilteritinib, venetoclax, low\u2010dose cytarabine and actinomycin D (G\u2010ACTIVE). G\u2010ACTIVE resulted in a 95% (19\/20) overall response rate and 75% (15\/20) complete remission and complete remission with an incomplete platelet recovery (CR\u2009+\u2009CRp) rate. Out of 13 transplant\u2010eligible patients, 11 (86%) proceeded to an allogeneic stem cell transplantation. The median overall survival and relapse\u2010free survival after G\u2010ACTIVE were 32 and 12.9\u2009months respectively. The Day 60 mortality rate was 15%.<\/jats:p>","DOI":"10.1111\/bjh.19318","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T06:21:05Z","timestamp":1706682065000},"page":"1227-1231","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gilteritinib in combination with venetoclax, low\u2010dose cytarabine and actinomycin D for relapsed or refractory <scp>FLT3<\/scp>\u2010mutated acute myeloid leukaemia"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-1534","authenticated-orcid":false,"given":"Andrius","family":"Zucenka","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Institute of Clinical Medicine Vilnius University  Vilnius Lithuania"},{"name":"Hematology, Oncology and Transfusion Medicine Centre Vilnius University Hospital Santaros Klinikos  Vilnius Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Griskevicius","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute of Clinical Medicine Vilnius University  Vilnius Lithuania"},{"name":"Hematology, Oncology and Transfusion Medicine Centre Vilnius University Hospital Santaros Klinikos  Vilnius Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011583"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157210"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00602"},{"key":"e_1_2_13_6_1","article-title":"P485: azacitidine, venetoclax and gilteritinib for patients with newly diagnosed FLT3\u2010mutated acute myeloid leukemia: a subgroup analysis from a phase II study","volume":"7","author":"Short N","year":"2023","journal-title":"Hema"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.244020"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00670-0"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7036"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3405"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144434"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01416-5"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121615"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0640"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01192-7"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0177"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00911-w"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:35:30Z","timestamp":1712763330000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bjh.19318"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19318","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"2023-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}